Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment

Reuters08-13

<a href="https://laohu8.com/S/LYRA">Lyra Therapeutics</a> Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment

Lyra Therapeutics Inc., a late-stage biotechnology company, has released a corporate presentation detailing its development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for treating chronic rhinosinusitis $(CRS)$. The company is currently advancing its lead program, LYR-210, aimed at approval for both non-polyp and polyp patients. The ENLIGHTEN 2 Phase 3 trial has successfully met its primary and key secondary endpoints, with pooled data showing consistent improvement over sham control in various endpoints. With a significant market opportunity in the U.S., where CRS affects approximately 12% of the population, Lyra's innovative treatment targets both CRS with and without nasal polyps. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyra Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2559621980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 04:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559621980","market":"us","top_or_hot":-1,"title":"Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a late-stage biotechnology company, has released a corporate presentation detailing its development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for treating chronic rhinosinusitis <a href=\"https://laohu8.com/S/CRS\">$(CRS)$</a>. The company is currently advancing its lead program, LYR-210, aimed at approval for both non-polyp and polyp patients. The ENLIGHTEN 2 Phase 3 trial has successfully met its primary and key secondary endpoints, with pooled data showing consistent improvement over sham control in various endpoints. With a significant market opportunity in the U.S., where CRS affects approximately 12% of the population, Lyra's innovative treatment targets both CRS with and without nasal polyps. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyra Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-13 04:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LYRA\">Lyra Therapeutics</a> Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a late-stage biotechnology company, has released a corporate presentation detailing its development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for treating chronic rhinosinusitis <a href=\"https://laohu8.com/S/CRS\">$(CRS)$</a>. The company is currently advancing its lead program, LYR-210, aimed at approval for both non-polyp and polyp patients. The ENLIGHTEN 2 Phase 3 trial has successfully met its primary and key secondary endpoints, with pooled data showing consistent improvement over sham control in various endpoints. With a significant market opportunity in the U.S., where CRS affects approximately 12% of the population, Lyra's innovative treatment targets both CRS with and without nasal polyps. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyra Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LYRA","symbol_name":"Lyra Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL1Fc237:1","article_id":"2559621980","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559621980","pubTimestamp":1755029821,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lyra Therapeutics Inc., a late-stage biotechnology company, has released a corporate presentation detailing its development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for treating chronic rhinosinusitis . The company is currently advancing its lead program, LYR-210, aimed at approval for both non-polyp and polyp patients. The ENLIGHTEN 2 Phase 3 trial has successfully met its primary and key secondary endpoints, with pooled data showing consistent improvement over sham control in various endpoints. With a significant market opportunity in the U.S., where CRS affects approximately 12% of the population, Lyra's innovative treatment targets both CRS with and without nasal polyps. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LYRA":"Lyra Therapeutics","BK4007":"制药"},"translate_title":"Lyra Therapeutics Inc.推出用于治疗慢性鼻窦炎的创新鼻腔药物植入物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LYRA":0.9},"content_text":"Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment\n    \n\n        Lyra Therapeutics Inc., a late-stage biotechnology company, has released a corporate presentation detailing its development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for treating chronic rhinosinusitis $(CRS)$. The company is currently advancing its lead program, LYR-210, aimed at approval for both non-polyp and polyp patients. The ENLIGHTEN 2 Phase 3 trial has successfully met its primary and key secondary endpoints, with pooled data showing consistent improvement over sham control in various endpoints. With a significant market opportunity in the U.S., where CRS affects approximately 12% of the population, Lyra's innovative treatment targets both CRS with and without nasal polyps. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyra Therapeutics Inc. published the original content used to generate this news brief on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2559621980","isCrawlerRequest":true}